Overview

Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

To evaluate the effect of rifampin, a cytochrome P450 3A (CYP3A) inducer, on the pharmacokinetics (PK) of IPI-145; to assess the safety and tolerability of IPI-145 when administered with rifampin in healthy subjects

Phase:

Phase 1

Details

Lead Sponsor:

Infinity Pharmaceuticals, Inc.
SecuraBio

Treatments:

Rifampin